Читать книгу Advances in Radiation Therapy - Группа авторов - Страница 45

Both hypoxia and the proliferation of imaging are illustrative for a more general challenge we face in the development of biomarker imaging for radiotherapy. Despite the many initiatives, based on many different biological characteristics, currently only a few biomarkers have the potency to enter clinical routine. These have to first overcome the challenge of nonuniformity in study designs, imaging, and quantification, which slows down further development by hampering the combination and comparison of results.

The value of the use of biomarkers lies in patient selection. The challenge of biomarker studies is to first select those patients that can demonstrate the working of the biomarker. By both biological and technical harmonization, biomarkers will further demonstrate their usefulness for radiotherapy. Biomarkers have the potency to be useful for both research and individual patients.